Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs

Mauro Gori, Maurizio Volterrani, Massimo F. Piepoli, Michele Senni

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Sacubritil. *. valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies.

Original languageEnglish
Pages (from-to)136-140
JournalInternational Journal of Cardiology
Volume226
DOIs
Publication statusPublished - Jan 2017

Fingerprint

Neprilysin
Angiotensin Receptors
Valsartan
Drug Combinations
Pharmaceutical Preparations
Heart Failure
Clinical Studies
LCZ 696

Keywords

  • Angiotensin receptor-neprilysin inhibitor
  • ARNi
  • Heart failure
  • LCZ696

ASJC Scopus subject areas

  • Medicine(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Angiotensin receptor-neprilysin inhibitor (ARNi) : Clinical studies on a new class of drugs. / Gori, Mauro; Volterrani, Maurizio; Piepoli, Massimo F.; Senni, Michele.

In: International Journal of Cardiology, Vol. 226, 01.2017, p. 136-140.

Research output: Contribution to journalArticle

@article{6fe16fa7820242d597ff5b7f8a4958ac,
title = "Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs",
abstract = "Sacubritil. *. valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies.",
keywords = "Angiotensin receptor-neprilysin inhibitor, ARNi, Heart failure, LCZ696",
author = "Mauro Gori and Maurizio Volterrani and Piepoli, {Massimo F.} and Michele Senni",
year = "2017",
month = "1",
doi = "10.1016/j.ijcard.2016.06.083",
language = "English",
volume = "226",
pages = "136--140",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Angiotensin receptor-neprilysin inhibitor (ARNi)

T2 - Clinical studies on a new class of drugs

AU - Gori, Mauro

AU - Volterrani, Maurizio

AU - Piepoli, Massimo F.

AU - Senni, Michele

PY - 2017/1

Y1 - 2017/1

N2 - Sacubritil. *. valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies.

AB - Sacubritil. *. valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies.

KW - Angiotensin receptor-neprilysin inhibitor

KW - ARNi

KW - Heart failure

KW - LCZ696

UR - http://www.scopus.com/inward/record.url?scp=85003545210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003545210&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2016.06.083

DO - 10.1016/j.ijcard.2016.06.083

M3 - Article

VL - 226

SP - 136

EP - 140

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -